CD274 and non-small cell lung carcinoma: The second highly-cited article, authored by Hossein (Borghaei et al., 2015) and published in the New England Journal of Medicine (cited 6,110 times), demonstrated that nivolumab outperformed docetaxel in terms of OS, with patients with advanced non-squamous NSCLC for whom platinum-based chemotherapy had failed benefiting from the increased efficacy of this drug owing to PD-L1 expression.